Fetal bovine serum - optima
Ended Awarded
- Contract number
- 75N91021F00003
- Awardee
-
Research And Diagnostic Systems, Inc. UEI WAYSQU5HJYT9 Part of Bio-Techne Corporation
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $14,976
Award facts
- Contract value 100% obligated
- $14,976.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325414 Biological Product (except Diagnostic) Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Minneapolis, MN 55413, USA
Award details come from SAM.gov/FPDS.
About this award
The National Cancer Institute awarded a $14,976 firm fixed-price Blanket Purchase Agreement (BPA) call to Research and Diagnostic Systems, Inc. (R&D Systems) on August 18, 2021, for the supply of Fetal Bovine Serum – Optima, with performance completion by September 30, 2021. The award was made through open competition with no set-aside designation. R&D Systems, a Minneapolis-based manufacturer of biological research materials and subsidiary of Bio-Techne Corporation, specializes in providing high-quality research reagents and laboratory supplies essential to biomedical research. The work will be performed in Minneapolis, Minnesota.
This task order represents a call against R&D Systems' larger $10 million single-award BPA with the Office of Logistics and Acquisition Operations, which runs through September 30, 2025, and covers comprehensive biological materials, laboratory supplies, and blood products supporting research across multiple National Institutes of Health institutes. Fetal bovine serum is a critical component in cell culture media widely used throughout cancer research, immunology studies, and other biomedical investigations, making R&D Systems' specialized supply capability valuable to the National Cancer Institute's research mission. The company has demonstrated consistent capability in supplying such materials to federal agencies through numerous prior contract awards spanning various NIH institutes.
Quick answers
Who was awarded contract 75N91021F00003?
75N91021F00003 was awarded to Research And Diagnostic Systems, Inc. by National Cancer Institute (National Institutes of Health) on August 18, 2021.
How much is contract 75N91021F00003 worth?
The government has obligated $14,976 on 75N91021F00003.
Is contract 75N91021F00003 an order under another contract?
Yes. 75N91021F00003 is a BPA call under HHSN263201600021B, a blanket purchase agreement.
Was contract 75N91021F00003 competed?
The extent of competition for 75N91021F00003 was competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award